As we reflect on the past year, we are deeply grateful for your membership and the vibrant community it sustains. The annual ICIS business meeting was held on November 21, 2024, via Zoom. If you were unable to participate, the recorded meeting is now available on-demand. [READ MORE]
My lab focuses on the development of novel immunotherapies for pediatric solid tumors. We take the most promising discoveries and translate them into the clinic. [READ MORE]
The International Cytokine & Interferon Society (ICIS) is proud to honor outstanding contributions to the field of cytokine and interferon research through its comprehensive awards program. Designed to recognize excellence at every stage of a scientist’s career, the ICIS awards underscore the Society’s commitment to fostering innovation, mentorship, and impactful [READ MORE]
Targeting EGFRvIII and CD47-SIRPα: A New CAR-T Strategy for Glioblastoma Treatment Review contributed by: PhD candidate Eugenio Contreras Castillo (one of the 2024 ICIS-Pfizer Trainee Award Winners for Most Promising Research Presentations at Cytokines 2024), Department of Cell Biology Institute of Cellular Physiology (IFC), National Autonomous University of Mexico (UNAM) [READ MORE]
1) Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis (ClinicalTrials.gov ID NCT05309616) | 2) Assessment of Serum interleukin10 Level in Patients With Immune Thrombocytopenic Purpura at Sohag University Hospital (ClinicalTrials.gov ID NCT05835050) | 3)Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma (DiTuSarc) (ClinicalTrials.gov ID NCT05080790) [READ MORE]
By Howard Young, Retired Principal Investigator, National Cancer Institute, Frederick, Maryland, USA Having been retired for 10 months, I thought I would provide a bit of advice of what to expect in retirement for someone who had a scientific career. Drs. Sharon Wahl and Charlie Glinka contributed some thoughts to [READ MORE]
There’s no doubt, Cytokines2024 in Seoul, Korea was a resounding success. The ICIS/KAI joint meeting boasted nearly 2,000 attendees from 36 countries, 55 invited speakers, 55 pharma and vendor sponsors, > 600 posters, 20 junior and senior research awards, 47 ICIS travel awards, and a Nobel Laureate. The conference was [READ MORE]
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma
New CSF Biomarkers for Alzheimer’s Disease (BioAD)
Interleukin and Autoantibodies in Myasthenia Gravis [READ MORE]
Well, it’s hard to believe it but October is here, and with it Cytokines2024! As I write this my bag is packed, my itinerary organized (sort of), and my excitement is mounting for my first trip to Seoul, Korea. The program is set, featuring Keynote speakers, Dr. Judith Allen (University [READ MORE]
My main research interest is to decipher how signals such those of the microbiota and metabolism regulate inflammatory diseases and infections of the respiratory tract. I am about to launch my independent scientific career and I am very grateful for the support of the ICIS through the Sydney and Joan [READ MORE]
International Cytokine & Interferon Society, Copyright 2024 Website Design by Rhema Association Management | Privacy Policy
